GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » EV-to-EBITDA

Hinova Pharmaceuticals (SHSE:688302) EV-to-EBITDA : -8.77 (As of Sep. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hinova Pharmaceuticals's enterprise value is ¥2,002.35 Mil. Hinova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-228.40 Mil. Therefore, Hinova Pharmaceuticals's EV-to-EBITDA for today is -8.77.

The historical rank and industry rank for Hinova Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

SHSE:688302' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.9   Med: -9.92   Max: -3.76
Current: -8.77

During the past 6 years, the highest EV-to-EBITDA of Hinova Pharmaceuticals was -3.76. The lowest was -20.90. And the median was -9.92.

SHSE:688302's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 8.74 vs SHSE:688302: -8.77

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-23), Hinova Pharmaceuticals's stock price is ¥27.89. Hinova Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-2.323. Therefore, Hinova Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Hinova Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Hinova Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals EV-to-EBITDA Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - - -8.42 -14.20

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.67 -10.20 -14.20 -7.73 -6.00

Competitive Comparison of Hinova Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Hinova Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hinova Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's EV-to-EBITDA falls into.



Hinova Pharmaceuticals EV-to-EBITDA Calculation

Hinova Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2002.347/-228.397
=-8.77

Hinova Pharmaceuticals's current Enterprise Value is ¥2,002.35 Mil.
Hinova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-228.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hinova Pharmaceuticals  (SHSE:688302) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hinova Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.89/-2.323
=At Loss

Hinova Pharmaceuticals's share price for today is ¥27.89.
Hinova Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-2.323.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Hinova Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hinova Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines